Genomic Health, Inc. (NASDAQ:GHDX) – Analysts at Jefferies Group issued their Q3 2017 earnings per share estimates for shares of Genomic Health in a research report issued on Friday. Jefferies Group analyst B. Couillard forecasts that the medical research company will earn ($0.01) per share for the quarter. Jefferies Group has a “Hold” rating and a $34.00 price target on the stock. Jefferies Group also issued estimates for Genomic Health’s Q1 2018 earnings at $0.07 EPS, Q2 2018 earnings at $0.07 EPS, Q3 2018 earnings at $0.07 EPS and FY2018 earnings at $0.27 EPS.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Genomic Health in a research report on Wednesday, September 27th. BidaskClub downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Cowen and Company reaffirmed a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $32.00.

TRADEMARK VIOLATION WARNING: “Equities Analysts Set Expectations for Genomic Health, Inc.’s Q3 2017 Earnings (GHDX)” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/23/equities-analysts-set-expectations-for-genomic-health-inc-s-q3-2017-earnings-ghdx.html.

Genomic Health (NASDAQ GHDX) opened at 33.72 on Monday. Genomic Health has a 12-month low of $26.37 and a 12-month high of $34.02. The company’s market cap is $1.17 billion. The company’s 50-day moving average price is $31.98 and its 200-day moving average price is $31.72.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business had revenue of $85.50 million for the quarter, compared to the consensus estimate of $86.08 million. During the same quarter in the previous year, the business posted ($0.18) EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis.

Institutional investors have recently added to or reduced their stakes in the company. Dubuque Bank & Trust Co. grew its position in shares of Genomic Health by 8.4% during the 2nd quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 379 shares during the period. SG Americas Securities LLC grew its position in shares of Genomic Health by 37.8% during the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after acquiring an additional 1,679 shares during the period. Legal & General Group Plc grew its position in shares of Genomic Health by 48.7% during the 1st quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 2,038 shares during the period. Parametric Portfolio Associates LLC grew its position in shares of Genomic Health by 5.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after acquiring an additional 441 shares during the period. Finally, Envestnet Asset Management Inc. grew its position in shares of Genomic Health by 13.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock valued at $259,000 after acquiring an additional 993 shares during the period. 88.90% of the stock is owned by hedge funds and other institutional investors.

In other news, insider James J. Vaughn sold 8,000 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total transaction of $244,720.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO G Bradley Cole sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $31.93, for a total transaction of $159,650.00. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock valued at $1,022,620 over the last three months. Insiders own 46.20% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.